- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05462613
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02)
Induction Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin Followed by Chemotherapy in Second Line Metastatic Colorectal Cancer Carcinoma An Open-label Randomized Phase II-III Study
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Angélique VIENOT, MD, PhD
- Phone Number: 00 33 3 81 47 99 99
- Email: angelique.vienot@gmail.com
Study Contact Backup
- Name: Christophe BORG, MD, PhD
- Phone Number: 00 33 3 81 47 99 99
- Email: xtoph.borg@gmail.com
Study Locations
-
-
-
Besançon, France
- Recruiting
- CHU de Besancon
-
Contact:
- Anéglique VIENOT, MD, PhD
-
Créteil, France
- Recruiting
- Hôpital Henri Mondor
-
Contact:
- Christophe TOURNIGAND
-
Dijon, France
- Recruiting
- Centre Georges Francois Leclerc
-
Contact:
- François GHIRINGHELLI, Pr
-
Lyon, France
- Recruiting
- Hopital Prive Jean Mermoz
-
Contact:
- Jérôme DESRAME, Dr
-
Lyon, France, 69000
- Not yet recruiting
- Centre Léon Bérard
-
Contact:
- Christelle DE LA FOUCHARDIERE, Pr
-
Montbeliard, France
- Recruiting
- Hopital Nord Franche Comte
-
Contact:
- Christophe BORG, Pr
-
Mulhouse, France
- Recruiting
- Groupe hospitalier de la région de Mulhouse et Sud Alsace
-
Contact:
- Stéphanie HUSSON-WETZEL, Dr
-
Paris, France
- Recruiting
- Hôpital Européen Georges Pompidou
-
Contact:
- Claire Gallois, Dr
-
Paris, France
- Recruiting
- Hopital Saint Antoine
-
Contact:
- Romain Cohen
-
Paris, France
- Recruiting
- Institut Mutualiste Montsouris
-
Contact:
- Emilie SOULARUE, Dr
-
Paris, France
- Not yet recruiting
- Hôpital La Pitié-Salpêtrière
-
Contact:
- Jean-Baptiste BACHET
-
Reims, France
- Not yet recruiting
- CHU de Reims - Hôpital Robert Debré
-
Contact:
- Olivier BOUCHE, Dr
-
Suresnes, France
- Not yet recruiting
- Hopital FOCH
-
Contact:
- Asmahane BENMAZIANE TEILLET
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with histologically proven metastatic colorectal cancer in progression after a first line of chemotherapy +/- targeted therapy
Patients must have been treated for their metastatic disease with one of the following regimens as first-line therapy:
- FOLFOX (Oxaliplatine, 5-Fluoro-uracil)
- FOLFIRI (Irinotecan, 5-Fluoro-uracil)
- FOLFIRINOX (Irinotecan, oxaplipatin, 5-Fluoro-uracil) or FOLFOXIRI (irinotecan, oxaliplatin, 5-Fluoro-uracil)
- FOLFOX and anti-VEGFA (bevacizumab only)
- FOLFIRI and anti-VEGFA (bevacizumab only)
- FOLFIRINOX or FOLFOXIRI and anti-VEGFA (bevacizumab only)
- FOLFOX and anti-EGFR (Epiderman Growth Factor Recepto)
- FOLFIRI and anti-EGFR
- FOLFIRINOX or FOLFOXIRI and anti-EGFR
Of note, a chemotherapy prescribed for metastases occurring within six months after the end of an adjuvant chemotherapy are considered as a second line of therapy.
Patients should have a history of resistance to first line chemotherapy defined by:
- Disease progression during the first line of their metastatic disease, less than 3 months after the last exposition to chemotherapy (even a chemotherapy regimen mentioned above or a 5-Fluoro-uracil-based maintenance therapy).
- Disease relapse within 6 months after the end of an adjuvant FOLFOX based chemotherapy.
- Disease relapse within 6 months after the surgical resection of metastases following a first line of chemotherapy.
- Life expectancy of at least 3 months
- Female or male with age ≥18 years old
- Performance status Eastern Cooperative Oncology Group World Health Organization (ECOG-WHO) ≤1 (Appendix 1),
- Measurable disease defined according to RECIST v1.1 (scanner or MRI)
- Molecular status: patients eligible should have microsatellite-stable (MSS) status, absence of BRAF V600E (B(Raf gene, val600-to-glu) mutation and a known RAS (Retrovirus Associated Sequences) status.
Adequate bone marrow, liver and renal functions.
- Haemoglobin ≥ 9 g/dL; absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L
- Total serum bilirubin ≤ 1.5 times upper normal value (ULN), serum alkaline phosphatase < 5 times ULN, aminotransferases (AST/ALT) ≤ 3 × ULN in absence of hepatic metastasis or ≤ 5 if presence of hepatic lesions
- Cockcroft glomerular filtration rate > 50 ml/min
- Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour
- No contraindication to Iodine contrast media injection during CT
- For female patients of childbearing potential, negative pregnancy test within 14 days before starting the study drug through at 210 days after the last dose of regorafenib. Men and women are required to use adequate birth control during the study (when applicable),
- Signed and dated informed consent,
- Ability to comply with the study protocol, in the Investigator's judgment.
- Registration in a national health care system (CMU included).
Exclusion Criteria:
- Diagnosis of additional malignancy within 2 years prior to the inclusion (exception of curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical and/or bladder cancer),
- Current participation in a study of an investigational agent. Patients might be included at least 21 days following the last investigational agent administration.
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion in the trial;
- Patient under judicial protection (curators, autorship) and/or deprived of freedom,
- Planned surgical procedure within the first month of treatment or any procedure that might change the timing of regorafenib administration during the first month of treatment,
- Previous exposure to regorafenib,
- Previous exposure to other anti-angiogenic treatment than bevacizumab,
- Complete deficit in dihydropyrimidine dehydrogenase (DPD),
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days before start of study medication,
- Pregnant or breast-feeding subjects,
- Congestive Heart Failure ≥ New York Heart Association (NYHA) class 2, unstable angina (anginal symptomatology at rest),
- Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months),
- Myocardial infarction less than 6 months before start of study drug,
- Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted),
- Uncontrolled hypertension (Systolic blood pressure >150 mmHg and/or diastolic pressure >100 mmHg despite optimal medical management), or history of hypertensive crisis, or hypertensive encephalopathy
- Pleural effusion or ascites that causes respiratory compromise (≥ CTCAE grade 2 dyspnea),
- Ongoing infection >grade 2 CTCAE V5 (Appendix 6 ),
- Known History of human immunodeficiency virus (HIV) infection,
- Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy,
- Subjects with seizure disorder requiring medication,
- History of organ allograft,
- Subjects with evidence or history of any bleeding diathesis, irrespective of severity,
- Any haemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication,
- Serious, Non-healing wound, active ulcer or untreated bone fracture,
- History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to inclusion,
- Dehydration CTCAE v4 grade ≥1,
- Known hypersensitivity to any of the study drugs, study drug classes or excipient in the formulation,
- Interstitial lung disease with ongoing signs or symptoms,
- Persistent proteinuria of CTCAE Grade 3 (>3.5 g/24 hours),
- Subject unable to swallow oral medications,
- Any malabsorption condition, unresolved toxicity higher than CTCAE (V4) Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neuropathy ≤ Grade 2,
- Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 3 weeks,
- Treatment with any other investigational medicinal product within 28 days prior to study entry, EXCEPT for ASPIRIN,
- Co-administration of drugs potentially interacting with regorafenib i.e. CYP3A4 or UGT1A9 (UDP-glucuronosyltransferase 1-9) inducers/inhibitors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Regorafenib + metronomic Capecitabine + metronomic Cyclophosphamide + low-dose Aspirin followed by second line of chemotherapy (Bevacizumab + FOLFOX or FOLFIRI)
|
EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.
5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
every 2 weeks according to investigator practice
75 mg orally and daily during two months
|
Active Comparator: Control
Second line of chemotherapy (Bevacizumab + FOLFOX or FOLFIRI)
|
EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
every 2 weeks according to investigator practice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best objective response during treatment period (phase II)
Time Frame: during treatment period (from first treatment administration and disease progression, an average of 14 months
|
the best response rate evaluated with RECIST v1.1 criteria per an independent radiologist committee during the treatment period defined as the number of with complete response (CR) or partial response (PR) as best response divided by the total number of patients evaluable.
Patients for whom best overall tumor response is not CR or PR will be considered non-responders.
|
during treatment period (from first treatment administration and disease progression, an average of 14 months
|
overall survival (OS) (phase III)
Time Frame: through study completion, an average of 64 months
|
Overall survival is defined as the time from the randomization to death from any cause.
|
through study completion, an average of 64 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aspirin
- Bevacizumab
Other Study ID Numbers
- 2022/702
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on quality of life questionnaires
-
Centre Hospitalier Universitaire DijonCompletedIdiopathic Pulmonary Fibrosis | Patient-caregiver DyadsFrance
-
University Hospital, GrenobleUniversity Grenoble AlpsNot yet recruitingChildhood Cancer | Adapted Physical ActivityFrance
-
Instituto do Cancer do Estado de São PauloCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Asten SanteRecruiting
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Assistance Publique Hopitaux De MarseilleUnknownAtaxia | Hemiparesis | Paraparesis | Neuromuscular Disorders | Tetraparesis | Extrapyramidal Motor DisordersFrance
-
Ramsay Générale de SantéEuropean Clinical Trial Experts NetworkRecruiting
-
Columbia UniversityRecruitingBreast Cancer | Ductal Carcinoma in SituUnited States
-
Memorial Sloan Kettering Cancer CenterThe Cleveland ClinicCompletedQuality of Life | Prostate CancerUnited States